Harrington v. Purdue Pharma L.P.

Wikipedia · Justia · Docket · oyez.org

Argued on Dec 4, 2023.

Petitioner: William K. Harrington, United States Trustee, Region 2.
Respondent: Purdue Pharma L.P., et al.

Advocates:

Curtis E. Gannon (for the Petitioner)
Gregory G. Garre (for Respondents Purdue Pharma L.P., et al.)
Pratik A. Shah (for Respondents The Official Committee of Unsecured Creditors of Purdue Pharma L.P., et al.)

Facts of the case (from oyez.org)

The Sackler family, who purchased Purdue Pharma in the 1950s, heavily influenced the company’s direction and was instrumental in the development and marketing of OxyContin. Despite initial claims of low addiction risk, growing evidence of widespread abuse led to legal battles across the United States, with multiple stakeholders including individuals, state governments, and federal agencies suing Purdue. In 2004, the board of Purdue entered into an expansive Indemnity Agreement to protect its directors and officers from financial liability related to lawsuits. This protection was especially broad, extending even after their official tenure at Purdue, but contained a bad faith carveout. From 2007 onwards, the Sacklers began shielding assets, anticipating litigation against them personally. By 2019, Purdue faced weakened financial prospects, and the Sacklers had stepped down from the board.

In the same year, the DOJ brought criminal and civil charges against Purdue, resulting in a plea agreement in 2020 that prioritized the DOJ’s claims in Purdue’s bankruptcy proceedings. The plea stipulated a $2 billion forfeiture judgment but allowed for the release of $1.775 billion if certain conditions were met. Although Purdue declared bankruptcy in 2019, the Sacklers did not, and litigation against both parties was temporarily halted. The estate of Purdue is estimated to be around $1.8 billion, while claims against both Purdue and the Sacklers are estimated to exceed $40 trillion.

The U.S. Bankruptcy Court for the Southern District of New York confirmed a proposed bankruptcy plan on September 17, 2021. This plan included a “shareholder release” that, in effect, permanently enjoined certain third-party claims against the Sacklers. Several parties objected to the plan, but the bankruptcy court rejected their claims. On appeal to the U.S. District Court for the Southern District of New York, the district court overturned the bankruptcy court's confirmation, holding that the Bankruptcy Code does not allow for the forced release of direct claims against non-debtors. The U.S. Court of Appeals for the Second Circuit reversed the district court’s order holding that the Bankruptcy Code does not permit nonconsensual third-party releases of direct claims, and affirmed the bankruptcy court’s approval of the plan.

Question

Does the Bankruptcy Code authorize a court to approve, as part of a plan of reorganization under Chapter 11 of the Bankruptcy Code, a release that extinguishes claims held by non-debtors against non-debtor third parties, without the claimants’ consent?

[23-124] Harrington v. Purdue Pharma L.P.

Supreme Court Oral Arguments